Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672454 | 0.81 | MGMT (0.41) | GAAPOLBNPSR1PDE4APDE4B | |
| SCHEMBL1767742 | 0.80 | ADORA2A (0.39) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL2113436 | 0.79 | ADORA2A (0.33) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL6265333 | 0.78 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL19296939 | 0.78 | GAA (0.35) | GAAPOLBNPSR1PNPKDM4E | |
| SCHEMBL10863614 | 0.78 | ADORA2A (0.38) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL6434440 | 0.78 | PNP (0.50) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL874734 | 0.77 | ADORA2A (0.45) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL9960806 | 0.77 | PNP (0.38) | PDE4APDE4BPDE4CPDE4DPNP | |
| SCHEMBL5048171 | 0.77 | PNP (0.39) | PDE4APDE4BPDE4CPDE4DPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436945-B2 | FOR ENHANCING THE CHEMOTHERAPEUTIC TREATMENT OF TUMOR CELLS IN A MAMMAL WITH AN ANTINEOPLASTIC ALKYLATING AGENT, WHICH CAUSES CYTOTOXIC LESIONS AT THE O6-POSITION OF GUANINE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT) INACTIVATOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF HEALTH AND HUMAN SERVICES | 2002-08-20 | — | — | US | disclosed |
| US-6333331-B1 | USEFUL IN INACTIVATING THE HUMAN DNA REPAIR PROTEIN O.SUP.6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-12-25 | — | — | US | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0523160-A1 | CARBO-NUCLEOSIDE DERIVATIVES | FROUD, Clive (GB) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991015488-A1 | CARBO-NUCLEOSIDE DERIVATIVES | FROUD, CLIVE (GB) | 1991-10-17 | — | — | WO | disclosed |